Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials – Trinity Bivalacqua
Sam Chang converses with Trinity Bivalacqua about treatments in non-muscle invasive bladder cancer, focusing on Cretostimogene grenadenorepvec (Creto), an oncolytic adenovirus, CG0070. Dr. Bivalacqua discusses trials exploring Creto’s efficacy in managing BCG-unresponsive CIS, emphasizing its dual mechanism of action: direct tumor lysis and immune system activation. Initial results from the…